Following an EU-approval of the company’s food supplement ingredient, popularly known as the “red wine-pill”, the Danish biotech company Fluxome Sciences A/S is ready to conquer the global market.
The information comes from Fluxome’s acting CEO, Jarne Elleholm, who is a partner in the Danish state investment fund, Vækstfonden. He was instated, when the contract with former CEO Steen Andersen was terminated in the fall of 2011. However, the company is still looking for a more permanent solution for the post. Vækstfonden is one of Fluxome’s investors.